Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Organofluorides Stories

2013-11-01 08:27:55

Findings Presented at 42nd Annual Child Neurology Society Meeting MAPLE GROVE, Minn., Nov. 1, 2013 /PRNewswire/ -- A new systematic review found that when compared with intravenous or rectally administered diazepam, intranasal midazolam was equally effective and demonstrated comparable safety for the treatment of acute seizure emergencies in pediatric patients. Findings from the systematic review were presented at the 42(nd) Annual Child Neurology Society meeting in Austin, Texas, October 30...

2013-10-31 12:25:01

Interviewed Payers Say Biomarker-Driven Prescribing is an NSCLC Market Access Lever, But Optimal Pivotal Trial Design is Also Key, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 31, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed medical oncologists across the EU5 (France, Germany, Italy, Spain, and the United Kingdom) currently prescribe the...

2013-10-31 08:32:38

ARRY-520 Multiple Myeloma Registration Study Expected in 2014 BOULDER, Colo., Oct. 31, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the first quarter of its fiscal year ending June 30, 2014. (Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO) Revenue for the first quarter of fiscal 2014 was $14.2 million, compared to $15.8 million for the same period in fiscal 2013. The cost of partnered programs increased to $10.7 million,...

2013-10-30 23:23:12

The Firm is actively investigating potential Januvia lawsuit claims on behalf of individuals who allegedly developed pancreatitis, pancreatic cancer or thyroid cancer as a result of taking the Type 2 diabetes medication. New York, NY (PRWEB) October 30, 2013 A federal Januvia lawsuit litigation (http://www.januvialawsuithelp.com/) continued to progress in October with an initial status conference to discuss matters related to claims over the Type 2 diabetes drug, as well as other...

2013-10-28 23:21:22

Reportbuyer.com just published a new market research report: Fluoropolymer Market, By Type (PTFE, PVDF, FEP, Fluoroelastomers) & Application (Automotive, Electrical & Electronics, Chemical Processing, Industrial) - Global Trends & Forecast to 2018. London (PRWEB) October 28, 2013 Fluoropolymers Market Analysis by Product Types, Applications & Geography - Trends & Global Forecasts (2011 - 2016) Fluoropolymers are specialized polymeric materials witnessing strong market...

2013-10-24 23:02:30

Bernstein Liebhard LLP is actively investigating potential Risperdal gynecomastia lawsuit claims on behalf of men and boys who may have developed male breast growth after taking the antipsychotic drug. New York, NY (PRWEB) October 24, 2013 A new Risperdal lawsuit (http://www.therisperdallawsuit.com/) alleging gynecomastia, or male breast growth, has been filed in a consolidated litigation underway in Pennsylvania state court, Bernstein Liebhard LLP reports. According to recent court...

2013-10-22 23:34:34

Court Documents Indicate that More than 200 Risperdal Lawsuits Are Now Pending in a Mass Tort Litigation in Pennsylvania’s Philadelphia Court of Common Pleas Columbus, OH (PRWEB) October 22, 2013 Risperdal lawsuits are now being evaluated by Wright & Schulte LLC, an experienced personal injury law firm, on behalf of young men and boys who developed gynecomastia (male breast growth) allegedly due to Risperdal. According to court documents, at least 230 Risperdal lawsuits are now...

2013-10-22 16:25:15

SAN DIEGO, Oct. 22, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the initiation of a Phase 1b/2 randomized clinical trial (S1313) of Halozyme's investigational drug PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in combination with modified FOLFIRINOX chemotherapy (mFOLFIRINOX) compared to mFOLFIRINOX treatment alone in patients with metastatic pancreatic adenocarcinoma. The trial, which will enroll approximately 144 patients, is being sponsored...

2013-10-22 12:29:59

ROCKVILLE, Md., Oct. 22, 2013 /PRNewswire/ -- EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced today the presentation of preclinical data for a study comparing the efficacy of ENMD-2076 against that of standard of care agents including sorafenib, doxorubicin, and 5-FU for human hepatocellular carcinoma (HCC) models. The results of the study were presented at AACR-NCI-EORTC International...

2013-10-22 12:29:36

LONDON, Oct. 22, 2013 /PRNewswire/ -- ViiV Healthcare today announced the submission of a regulatory application in the United States for its investigational single-tablet regimen (STR) combining dolutegravir, abacavir and lamivudine for the treatment of people living with HIV-1. This New Drug Application (NDA) follows the approval of dolutegravir by the US Food and Drug Administration (FDA) in August 2013 under the brand name Tivicay(®), approved for use in combination with other...